SAGE Therapeutics IPO Info
Company Name: SAGE Therapeutics
Stock Symbol: SAGE
Exchange: NASDAQ
Status: Priced
IPO Date: 7/18/2014
IPO Price:
27.00 (
35.56%)
Underwriters
J.P. Morgan Securities LLC and Goldman, Sachs & Co
Amount of Offering: N/A
Number of Shares Offered: 5 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
SAGE Therapeutics is a biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for SRSE and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGEâ's proprietary chemistry platform has generated multiple new compounds that target GABAA and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. SAGE Therapeutics is a private company launched in 2010 by an experienced team of R&D leaders, CNS experts and investors.
News Headlines
